Systematic investigation of non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs)

被引：6
|
作者：
Beyer, A
Lawtrakul, L
Hannongbua, S
Wolschann, P
机构：
[1] Res Inst Mol Pathol, A-1030 Vienna, Austria
[2] Thammasat Univ, SIIT, Dept Common & Grad Studies, Pathum Thani 12121, Thailand
[3] Kasetsart Univ, Fac Sci, Dept Chem, Bangkok 10900, Thailand
[4] Inst Theoret Chem & Struct Biol, A-1090 Vienna, Austria
来源：
MONATSHEFTE FUR CHEMIE | 2004年 / 135卷 / 08期
关键词：
non-nucleoside reverse transcriptase inhibitors (NNRTIs); inhibition mechanism; viral mutation; drug resistance;
D O I：
10.1007/s00706-004-0173-y
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The 44 crystal structures of NNRTIs complexed with HIV-1 reverse transcriptase (RT) have been analyzed in detail especially the orientation geometries and the distances between inhibitor molecules and surrounding amino acids. In general, various NNIs bind to the same region of the HIV-1 RT in the palm subdomain of p66, but subtle differences in individual interactions between RT and its inhibitors can be detected by comparison of all structures in this study.
引用
收藏
页码：1047 / 1059
页数：13
相关论文
共 50 条
  • [21] HIV-1 non-nucleoside reverse transcriptase inhibitor
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1998, 3 (08) : 387 - 387
  • [22] Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    Vanangamudi, Murugesan
    Palaniappan, Senthilkumar
    Kathiravan, Muthu Kumaradoss
    Namasivayam, Vigneshwaran
    VIRUSES-BASEL, 2023, 15 (10):
  • [23] Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present, and future
    De Clercq, E
    CHEMISTRY & BIODIVERSITY, 2004, 1 (01) : 44 - 64
  • [24] Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors
    Thammaporn, Ratsupa
    Ishii, Kentaro
    Yagi-Utsumi, Maho
    Uchiyama, Susumu
    Hannongbua, Supa
    Kato, Koichi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (03) : 450 - 454
  • [25] Docking study of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Zhou, ZG
    Madrid, M
    Madura, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : U465 - U465
  • [26] Lead Optimization of Diarylpyrimidines as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase
    Zeng, Zhao-Sen
    Liang, Yong-Hong
    Feng, Xiao-Qing
    Chen, Fen-Er
    Pannecouque, Christophe
    Balzarini, Jan
    De Clercq, Erik
    CHEMMEDCHEM, 2010, 5 (06) : 837 - 840
  • [27] Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
    Chong, Pek
    Sebahar, Paul
    Youngman, Michael
    Garrido, Dulce
    Zhang, Huichang
    Stewart, Eugene L.
    Nolte, Robert T.
    Wang, Liping
    Ferris, Robert G.
    Edelstein, Mark
    Weaver, Kurt
    Mathis, Amanda
    Peat, Andrew
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (23) : 10601 - 10609
  • [28] The synthesis of several tritiated non-nucleoside, HIV-1 reverse transcriptase inhibitors
    Hamill, Terence G.
    Brenner, Nancy J.
    Eng, Wai-Si
    Burns, H. Donald
    Journal of Labelled Compounds and Radiopharmaceuticals, 1998, 41 (04): : 319 - 327
  • [29] Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors
    Famiglini, Valeria
    Coluccia, Antonio
    Brancale, Andrea
    Pelliccia, Sveva
    La Regina, Giuseppe
    Silvestri, Romano
    FUTURE MEDICINAL CHEMISTRY, 2013, 5 (18) : 2141 - 2156
  • [30] Integrating non-nucleoside reverse transcriptase inhibitors (NNRTIs) into clinical practice
    Montaner, JSG
    Harrigan, R
    Jahnke, N
    Yip, B
    Hogg, R
    Montessori, V
    O'Shaughnessy, MV
    AIDS, 1998, 12 : S7 - S7
12345